Today: 7 February 2026
Subscribe
Browse Category

PSE:GLO News 4 January 2026

Singapore stock market: GDP surprise, UOB buyback and global rates to watch before Jan 5 open

Singapore stock market: GDP surprise, UOB buyback and global rates to watch before Jan 5 open

SINGAPORE, Jan 4, 2026, 14:40 ET — Market closed Singapore shares head into Monday’s open with a stronger domestic growth backdrop after official data showed the economy expanded 4.8% in 2025, lifted by a 5.7% rise in fourth-quarter GDP.  Ministry of Trade and Industry That matters now because the advance estimates set expectations for early-2026 policy and profit outlooks, with investors also watching whether export-driven sectors can extend momentum as global rates stay sticky.  Reuters The benchmark Straits Times Index (STI) ended Friday’s session up 0.2% at 4,656.12, with traders likely to treat the 4,650 area as a near-term line
4 January 2026
···

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Go toTop